Chemokine Receptor Expression Pattern Correlates to Progression of Conjunctival Melanocytic Lesions

Ipenburg, Jolique A van; Waard, Nadine E de; Naus, Nicole; Jager, Martine J.; Paridaens, Dion; Verdijk, Robert M.

doi:10.1167/iovs.19-27162

Cited by 9 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Next, the percentage of stained cells that showed the predominant intensity, was determined; no positive cells were scored as 0% and less than 10%, 10% to 50%, 51% to 80%, and more than 80% were scored as 1, 2, 3, or 4, respectively. Then, IRS was calculated by multiplying the score for percentage of stained cells with the score for the intensity of the staining [41].…”

Section: Abhd6 Immunohistochemistrymentioning

confidence: 99%

Identification of Early-Onset Metastasis in SF3B1 Mutated Uveal Melanoma

Drabarek

Riet

Nguyen

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Approximately 25% of all uveal melanoma (UM) contain driver mutations in the gene encoding the spliceosome factor SF3B1, and whilst patients with such SF3B1 mutations generally have an intermediate risk on developing metastatic disease, a third of these patients develop early metastasis within 5 years after diagnosis. We therefore investigated whether clinical and/or genetic variables could be indicative of short progression-free survival (PFS < 60 months) or long PFS (PFS ≥ 60 months) for SF3B1-mutated (SF3B1mut) UM patients. We collected 146 SF3B1mut UM from our Rotterdam Ocular Melanoma Studygroup (ROMS) database and external published datasets. After stratification of all SF3B1mut UM using short PFS vs. long PFS, only largest tumor diameter (LTD) was significantly larger (mean: 17.7 mm (±2.8 SD) in the short PFS SF3B1mut group vs. the long PFS group (mean: 14.7 (±3.7 SD, p = 0.001). Combined ROMS and The Cancer Genome Atlas (TCGA) transcriptomic data were evaluated, and we identified SF3B1mut-specific canonical transcripts (e.g., a low expression of ABHD6 indicative for early-onset metastatic disease) or distinct expression of SF3B1mut UM aberrant transcripts, indicative of early- or late-onset or no metastatic SF3B1mut UM.

show abstract

Section: Abhd6 Immunohistochemistrymentioning

confidence: 99%

Identification of Early-Onset Metastasis in SF3B1 Mutated Uveal Melanoma

Drabarek

Riet

Nguyen

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…For these stainings an immunoreactive score (IRS) was determined as has been described in a previous report. 13 First, intensity of the staining was classified as absent (0), mild (1), moderate (2) or intense (3). Secondly, percentage of stained cells that showed the predominant intensity was scored as no positive cells (0), less than 10% (1), 10% to 50% (2), 51% to 80% (3), and more than 80% (4).…”

Section: Methodsmentioning

confidence: 99%

Accelerated growth of orbital schwannomas during pregnancy does not correlate with sex hormone- or growth factor receptor status

Hötte

Meijer

Verdijk

et al. 2020

Orbit

View full text Add to dashboard Cite

Purpose: Until now, three cases of growth of an orbital schwannoma during pregnancy have been published. We aim to provide additional insight in the effect of pregnancy on orbital schwannomas. Methods: We present two additional cases of accelerated growth of orbital schwannomas during pregnancy and investigate receptor expression profiles for estrogen, progesterone, androgen, VEGF, EGF, FGF, PDGF-Rβ and ki-67 in the two pregnant cases and six non-pregnant cases. Results: Case 1: A 26-year-old woman developed unilateral exophthalmos during pregnancy, with normal visual acuity and ocular motility. During a subsequent pregnancy, again the exophthalmos progressed. MRI showed a mass suggestive of schwannoma. After delivery, resection of the lesion was performed through an anterior approach. Pathology confirmed schwannoma. The expression profile was positive for estrogen-and FGF receptors and ki-67, but negative for progesterone-, androgen-and other growth factor receptors. Case 2: A 24-year-old woman presented with diplopia and unilateral pain during pregnancy. She had normal visual acuity, but a mild exophthalmos and elevation deficit. MRI revealed an extraconal mass suggestive of schwannoma. After delivery, resection was performed through an anterior approach. Pathology confirmed the diagnosis. The expression profile was positive for ki-67, but negative for sex hormone-and growth factor receptors. In the six non-pregnant cases the expression profiles varied, with only one subject showing a strong expression of estrogen-, progesterone-and androgen receptors. Conclusions: Orbital schwannomas can experience growth during pregnancy. The underlying mechanism remains unclear as hormone-and growth factor expression profiles show no correlation to the pregnant state.

show abstract

“…Several studies have shown that an outgrowth of lymphatic vessels is concomitant with the development of CM, possibly due to the increased expression of lymphangiogenic and chemotactic factors at the invasive edge of CM [ 30 , 31 , 32 ]. This mechanism could also explain the migration to and invasion of CM cells into the lymphatic vessels [ 33 , 34 ]. This prolymphangiogenic potential does not seem to be only associated with CM cells, but could also involve cells present in the TME [ 35 ].…”

Section: Biology Of Conjunctival Melanomamentioning

confidence: 99%

Small but Challenging Conjunctival Melanoma: New Insights, Paradigms and Future Perspectives

Nahon-Estève

Bertolotto

Picard‐Gauci

et al. 2021

Cancers

View full text Add to dashboard Cite

Although its incidence has increased over the last decades, conjunctival melanoma (CM) remains a rare but challenging periocular malignancy. While there is currently no recognized standard of care, “no-touch” surgical excision followed by adjuvant treatments is usually recommended. Despite its small size, managing CM is challenging for clinicians. The first challenge is the high risk of tumour local recurrence that occurs in about one third of the patients. The management of locally advanced CM (≥T2) or multiple recurrences may require mutilating surgeries such as orbital exenteration (OE). The second challenge is the metastatic spread of CM that occurs in about one quarter of patients, regardless of whether complete surgical excision is performed or not. This highlights the infiltrative and highly aggressive behaviour of CM. Recently, attention has been directed towards the use of eye-sparing strategies to avoid OE. Initially, wide conservative surgeries followed by customized brachytherapy or radiotherapy have appeared as viable strategies. Nowadays, new biological insights into CM have revealed similarities with cutaneous melanoma. These new findings have allowed clinicians to reconsider the management of locally advanced CM with “medical” eye-sparing treatment as well as the management of metastatic spread. The aim of this review was to summarize the current and future perspectives of treatment for CM based on recent biological findings.

show abstract

Chemokine Receptor Expression Pattern Correlates to Progression of Conjunctival Melanocytic Lesions

Cited by 9 publications

References 29 publications

Identification of Early-Onset Metastasis in SF3B1 Mutated Uveal Melanoma

Identification of Early-Onset Metastasis in SF3B1 Mutated Uveal Melanoma

Accelerated growth of orbital schwannomas during pregnancy does not correlate with sex hormone- or growth factor receptor status

Small but Challenging Conjunctival Melanoma: New Insights, Paradigms and Future Perspectives

Contact Info

Product

Resources

About